RRx-001

RRx-001 is an anticancer agent. It inhibits growth in a panel of 12 cancer cell lines (IC50s =1.8-6 µM), an effect that is enhanced in SCC VII cells under hypoxic conditions. RRx-001 increases intracellular levels of reactive oxygen species (ROS) in HT-29 and SCC VII cells in a concentration- and time-dependent manner and induces apoptosis in SCC VII, HL-60, and Daudi cells when used at concentrations of 5, 5, and 4 µM, respectively. RRx-001 (5 mg/kg per day for five days) reduces tumor growth and enhances radiation-induced tumor growth reduction in an SCC VII murine squamous cell carcinoma model. Pre-incubation of red blood cells and hemolysate with RRx-001 (3 mM) increases nitrite-induced nitric oxide (NO) release under hypoxic conditions. RRx-001 (10 mg/kg) also decreases parasitemia and increases survival in a mouse model of P. berghei ANKA infection.Formal Name: 2-bromo-1-(3,3-dinitro-1-azetidinyl)-ethanone. CAS Number: 925206-65-1. Synonyms: ABDNAZ. Molecular Formula: C5H6BrN3O5. Formula Weight: 268.0. Purity: >95%. Formulation: (Request formulation change), A solid. Solubility: DMF: 30 mg/ml, DMSO: 30 mg/ml, Ethanol: 2 mg/ml. SMILES: BrCC(N1CC([N+]([O-])=O)([N+]([O-])=O)C1)=O. InChi Code: InChI=1S/C5H6BrN3O5/c6-1-4(10)7-2-5(3-7,8(11)12)9(13)14/h1-3H2. InChi Key: JODKFOVZURLVTG-UHFFFAOYSA-N.